Powered by OpenAIRE graph
Found an issue? Give us feedback
View all 3 versions

Horizon Discovery Limited

corporate_fareorganization
Web page: http://www.horizondiscovery.com
Country: United Kingdom

Horizon Discovery Limited

6 Projects, page 1 of 2

  • 4DCELLFATE (Developing a global understanding of the PRC and NuRD complexes in stem cell differentiation, in health and disease)

    image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Open Access Mandate for Publications assignment_turned_inProject2011 - 2016Partners:THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE, Kobe University, IEO, UCPH, UAntwerpen +14 partners
    Funder: European Commission Project Code: 277899
    more_vert

  • GUIDE.MRD (GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD)

    image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Open Access Mandate for Publications and Research data assignment_turned_inProject2023 - 2028Partners:INNOVATION ACTA SRL, BMS, AUH, DiCE, Roche (Switzerland) +36 partners
    Funder: European Commission Project Code: 101112066
    Overall Budget: 34,948,400 EURFunder Contribution: 17,661,000 EUR

    Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved outcomes depends on clinical implementation of novel diagnostic technologies. For most cancer types the risk-features used to select individuals for post-operative adjuvant multimodal therapy are suboptimal, where many patients are overtreated and others undertreated. Liquid biopsy has opened a new diagnostic avenue to detect and monitor minimal residual disease (MRD) in individual cancer patients, especially for selecting patients for multi-modal therapies post-operatively. However, despite many circulating tumor DNA (ctDNA) diagnostics being developed there is a lack of standardization, harmonization, and robust data to demonstrate clinical validity. GUIDE.MRD is a consortium of leading academics, technology companies, pharmaceutical companies, and experts in multi-stakeholder engagements. Together, we will tackle the critical questions by developing reference standards for ctDNA diagnostics, clinically validate promising ctDNA diagnostics and develop data to guide the use of multi-modal therapies with a non-invasive diagnostic test. With robust engagement with regulatory authorities, payers and importantly patients themselves, we will develop recommendations and guidelines based on objective data to use ctDNA diagnostics to guide multi-modal therapy selection to improve patient outcomes.

    more_vert

  • COLTHERES (Modelling and predicting sensitivity to targeted therapies in colorectal cancers)

    image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Open Access Mandate for Publications assignment_turned_inProject2011 - 2014Partners:KUL, Horizon Discovery Limited, ARTTIC, Horizon Discovery Limited, ISB +14 partners
    Funder: European Commission Project Code: 259015
    more_vert

  • SEABIOTECH (From sea-bed to test-bed: harvesting the potential of marine microbes for industrial biotechnology)

    assignment_turned_inProject2012 - 2016Partners:SAMS, University of Würzburg, MATIS OHF, MBL, MATIS OHF +19 partners
    Funder: European Commission Project Code: 311932
    more_vert

  • PREDICT (Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics)

    image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Open Access Mandate for Publications assignment_turned_inProject2011 - 2014Partners:QMUL, Institut Gustave Roussy, EPO, AP-HP, DTU +18 partners
    Funder: European Commission Project Code: 259303
    more_vert
  • chevron_left
  • 1
  • 2
  • chevron_right

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected
arrow_drop_down

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.